Camp4 Therapeutics (CAMP) Cash from Financing Activities (2023 - 2026)

Camp4 Therapeutics has reported Cash from Financing Activities for 4 years, with the latest figure at $57000.0 in Q1 2026.

• Quarterly Cash from Financing Activities rose 137.75% year-over-year to $57000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $76.1 million (up 6.11% YoY) and the FY2025 annual result came in at $75.9 million, up 5.9% from the prior year.
• Cash from Financing Activities declined to $57000.0 in Q1 2026 per CAMP's latest filing, from $28.6 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $73.1 million in Q4 2024 and troughed at -$812000.0 in Q2 2024.
• A 4-year average of $14.8 million and a median of -$3000.0 in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities jumped 116071.43% in 2024, then slumped 60.88% in 2025.
• Over 4 years, Cash from Financing Activities stood at -$63000.0 in 2023, then surged by 116071.43% to $73.1 million in 2024, then plunged by 60.88% to $28.6 million in 2025, then slumped by 99.8% to $57000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $57000.0, $28.6 million, and $47.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.